Common medicines can fight obesity and diabetes, scientists say.medical research

Scientists have identified a variety of commonly used pharmaceuticals that can be repurposed to treat people suffering from obesity and diabetes.

Medicines set to be outlined at the International Conference on Obesity in Melbourne this weekend include treatments for gastric ulcers and heart rhythm disturbances and were identified using sophisticated computer programs.

Professor Murray Cairns, University of Newcastle, New South Wales, Australia, said:

“Our technology is harnessing genetically-informed precision medicine to identify and target novel therapies for these complex diseases.”

Agents selected as potential obesity agents include the muscle relaxant baclofen and carfilzomib, a drug used in chemotherapy. For potential diabetes treatments, researchers identified palbociclib, which is used to treat breast cancer, and cardiac glycosides, which are used to treat heart failure and heartbeat disorders.

In addition, we have identified drugs that have the potential to treat both obesity and diabetes. These include sucralfate, which is used to treat stomach ulcers, and the cancer drug regorafenib.

Repurposing existing drugs to tackle new conditions is becoming an increasingly attractive option for treating diseases such as diabetes. The safety of these medicines has already been studied during initial drug trials, so less time and cost is required to bring them to market.

Additionally, older drugs may no longer be subject to patent restrictions, which should make them cheaper for doctors and hospitals to manage.

Cairns and his colleague William Ray studied data on genetic pathways involved in the development of diabetes and obesity and used software to compare this information on the pathways that existing drugs take through the human body. did. They were able to identify an existing drug that could be reused to address two conditions.

“We wanted to impact these and other complex conditions through the discovery of drugs that target each individual’s genetically encoded biological risks.

The potential for developing new treatments for diabetes is encouraging. The number of cases has been steadily increasing worldwide over the last few decades and is associated with rising rates of obesity and physical inactivity among individuals.

“Diabetes and obesity are major risk factors for dozens of chronic health conditions that contribute to alarming levels of human morbidity and mortality,” said Reay.

Two-thirds of adults in the UK are over a healthy weight and half of them live with obesity. This is associated with reduced life expectancy and increased incidence of cardiovascular disease, liver and respiratory disease, and cancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button